Compare · BLCO vs COO
BLCO vs COO
Side-by-side comparison of Bausch + Lomb Corporation (BLCO) and The Cooper Companies Inc. (COO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLCO and COO operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- COO is the larger of the two at $19.03B, about 3.3x BLCO ($5.82B).
- Over the past year, BLCO is up 40.8% and COO is down 23.1% - BLCO leads by 64.0 points.
- BLCO has been more active in the news (17 items in the past 4 weeks vs 14 for COO).
- COO has more recent analyst coverage (25 ratings vs 18 for BLCO).
- Company
- Bausch + Lomb Corporation
- The Cooper Companies Inc.
- Price
- $16.30+2.58%
- $62.37-0.83%
- Market cap
- $5.82B
- $19.03B
- 1M return
- -1.90%
- -12.68%
- 1Y return
- +40.82%
- -23.15%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NYSE
- IPO
- 2022
- News (4w)
- 17
- 14
- Recent ratings
- 18
- 25
Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions. It offers intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
The Cooper Companies Inc.
The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.
Latest BLCO
- Director Robertson Russel C was granted 1,611 shares, increasing direct ownership by 2% to 78,418 units (SEC Form 4)
- Director Paulson John was granted 1,375 shares, increasing direct ownership by 2% to 73,981 units (SEC Form 4)
- Director Collis Steven H was granted 1,415 shares, increasing direct ownership by 6% to 26,161 units (SEC Form 4)
- Director Alfonso Eduardo was granted 1,375 shares, increasing direct ownership by 10% to 15,230 units (SEC Form 4)
- Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting
- SEC Form 10-Q filed by Bausch + Lomb Corporation
- Bausch + Lomb Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook
- President, GPIC Stewart Andrew J. covered exercise/tax liability with 4,216 shares, decreasing direct ownership by 5% to 86,433 units (SEC Form 4) (for tax liability)
- EVP & Chief Legal Officer Bailey A Robert D covered exercise/tax liability with 15,806 shares, decreasing direct ownership by 6% to 230,684 units (SEC Form 4) to satisfy withholding obligation
Latest COO
- CooperCompanies Announces Release Date for Second Quarter 2026
- SEC Form 4 filed by Rosebrough Walter M Jr
- CooperVision Partners with Canadian Olympic Speed Skater Valérie Maltais on Her Continued Pursuit of Excellence on the World Stage
- CooperVision Launches MADE BETTER™ Promise Beginning with MyDay® Contact Lenses*¹
- Telix Strengthens Board with Additional Director Appointments
- The Cooper Companies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Weiss Robert S
- SEC Form 4 filed by Rivas Maria
- SEC Form 4 filed by Jay Colleen
- SEC Form 4 filed by Carbone Barbara